Core Insights - Novartis is set to present data from 27 abstracts related to its Immunology portfolio at the 2025 ACR Convergence, including pivotal Phase III results for ianalumab in Sjögren's disease and biomarker data for rapcabtagene autoleucel in systemic lupus erythematosus [1][7] Group 1: Ianalumab and Sjögren's Disease - Ianalumab is an investigational therapy that may become the first targeted treatment for Sjögren's disease, which currently lacks FDA-approved options [2] - The NEPTUNUS-1 and NEPTUNUS-2 trials demonstrated significant reductions in disease activity for patients with Sjögren's disease [5][7] - Presentations will include insights into the dual mode of action of ianalumab, focusing on B cell depletion and blockade of B cell activating factor receptor signaling [3][5] Group 2: Rapcabtagene Autoleucel - Rapcabtagene autoleucel is a novel CAR-T cell therapy being evaluated for its potential to reset the immune system in severe refractory systemic lupus erythematosus [3][7] - Biomarker data from an ongoing Phase 1/2 study will be presented, suggesting a reset of the B cell compartment in patients with severe refractory SLE [8] Group 3: Cosentyx Data - Real-world data on Cosentyx (secukinumab) will be shared, particularly in relation to its use in psoriatic arthritis [3][8] - The data will compare the incidence of psoriatic arthritis in patients treated with different interleukin inhibitors [8] Group 4: Investor Engagement - Following the ACR event, Novartis will host a conference call for investors to discuss updates on its Immunology pipeline [4]